Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Updated on 10 December 2020
measurable disease
metastatic cancer


The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.



For more information, please contact Incyte Corporation at 1.855.463.3463

Condition Metastatic Cancers, Advanced Malignancies
Clinical Study IdentifierTX216937
Last Modified on10 December 2020


Yes No Not Sure

Inclusion Criteria

Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent
Phase 1: Subjects with advanced or metastatic solid tumors
Phase 1: Subjects who have disease progression after treatment with available therapies
Phase 2: Subjects with advanced or metastatic cervical cancer, gastric cancer (including stomach, esophageal, and GEJ), SCCHN and PD-1/PD-L1 relapsed melanoma
Presence of measurable disease based on RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

Exclusion Criteria

Laboratory and medical history parameters not within the Protocol-defined range
Prior treatment with any tumor necrosis factor super family agonist
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy
Active autoimmune disease
Known active central nervous system metastases and/or carcinomatous meningitis
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation
Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note